CN Patent

CN110563747A — 抗hiv化合物及其晶型

Assigned to Gilead Sciences Inc · Expires 2019-12-13 · 6y expired

What this patent protects

本发明涉及(2R,5S,13aR)‑7,9‑二氧代‑10‑((2,4,6‑三氟苯甲基)氨基甲酰基)‑2,3,4,5,7,9,13,13a‑八氢‑2,5‑桥亚甲基吡啶并[1’,2’:4,5]吡嗪并[2,1‑b][1,3]氧氮杂 ‑8‑酚钠形式I。

USPTO Abstract

本发明涉及(2R,5S,13aR)‑7,9‑二氧代‑10‑((2,4,6‑三氟苯甲基)氨基甲酰基)‑2,3,4,5,7,9,13,13a‑八氢‑2,5‑桥亚甲基吡啶并[1’,2’:4,5]吡嗪并[2,1‑b][1,3]氧氮杂 ‑8‑酚钠形式I。

Drugs covered by this patent

bictegravir-sodium (BICTEGRAVIR SODIUM)

Patent Metadata

Patent number: CN110563747A
Jurisdiction: CN
Classification: —
Expires: 2019-12-13
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.